IMVT
Price
$16.77
Change
+$0.75 (+4.68%)
Updated
Jun 6 closing price
Capitalization
2.87B
60 days until earnings call
XENE
Price
$31.64
Change
+$0.91 (+2.96%)
Updated
Jun 6 closing price
Capitalization
2.43B
61 days until earnings call
Interact to see
Advertisement

IMVT vs XENE

Header iconIMVT vs XENE Comparison
Open Charts IMVT vs XENEBanner chart's image
Immunovant
Price$16.77
Change+$0.75 (+4.68%)
Volume$2.18M
Capitalization2.87B
Xenon Pharmaceuticals
Price$31.64
Change+$0.91 (+2.96%)
Volume$576.17K
Capitalization2.43B
IMVT vs XENE Comparison Chart
Loading...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMVT vs. XENE commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a StrongBuy and XENE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (IMVT: $16.77 vs. XENE: $31.64)
Brand notoriety: IMVT and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 152% vs. XENE: 49%
Market capitalization -- IMVT: $2.87B vs. XENE: $2.43B
IMVT [@Biotechnology] is valued at $2.87B. XENE’s [@Biotechnology] market capitalization is $2.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • IMVT’s TA Score: 4 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both IMVT and XENE are a good buy in the short-term.

Price Growth

IMVT (@Biotechnology) experienced а +12.93% price change this week, while XENE (@Biotechnology) price change was +9.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

IMVT is expected to report earnings on Aug 06, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMVT($2.87B) has a higher market cap than XENE($2.43B). XENE YTD gains are higher at: -19.286 vs. IMVT (-32.297). XENE has higher annual earnings (EBITDA): -276.74M vs. IMVT (-404.87M). XENE has more cash in the bank: 627M vs. IMVT (375M). IMVT has less debt than XENE: IMVT (23K) vs XENE (9.02M). IMVT (0) and XENE (0) have equivalent revenues.
IMVTXENEIMVT / XENE
Capitalization2.87B2.43B118%
EBITDA-404.87M-276.74M146%
Gain YTD-32.297-19.286167%
P/E RatioN/AN/A-
Revenue00-
Total Cash375M627M60%
Total Debt23K9.02M0%
FUNDAMENTALS RATINGS
IMVT vs XENE: Fundamental Ratings
IMVT
XENE
OUTLOOK RATING
1..100
198
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10046
SMR RATING
1..100
9460
PRICE GROWTH RATING
1..100
6385
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
4050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (45) in the null industry is in the same range as XENE (76) in the Biotechnology industry. This means that IMVT’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (46) in the Biotechnology industry is somewhat better than the same rating for IMVT (100) in the null industry. This means that XENE’s stock grew somewhat faster than IMVT’s over the last 12 months.

XENE's SMR Rating (60) in the Biotechnology industry is somewhat better than the same rating for IMVT (94) in the null industry. This means that XENE’s stock grew somewhat faster than IMVT’s over the last 12 months.

IMVT's Price Growth Rating (63) in the null industry is in the same range as XENE (85) in the Biotechnology industry. This means that IMVT’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for IMVT (100) in the null industry. This means that XENE’s stock grew significantly faster than IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTXENE
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
72%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 10 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
71%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FNWFX86.210.19
+0.22%
American Funds New World F3
DBMYX29.62N/A
N/A
BNY Mellon Sm/Md Cp Gr Y
CHTCX17.54N/A
N/A
Invesco Charter C
JMNAX14.75N/A
N/A
JPMorgan Research Market Neutral A
SRFMX14.56N/A
N/A
Sarofim Equity

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+4.68%
ROIV - IMVT
60%
Loosely correlated
+0.27%
OCUL - IMVT
49%
Loosely correlated
+6.62%
COGT - IMVT
49%
Loosely correlated
+13.52%
KYMR - IMVT
48%
Loosely correlated
-0.08%
XENE - IMVT
48%
Loosely correlated
+2.96%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+2.96%
IDYA - XENE
55%
Loosely correlated
+2.99%
ATXS - XENE
54%
Loosely correlated
+14.75%
CRNX - XENE
54%
Loosely correlated
+2.13%
KYMR - XENE
49%
Loosely correlated
-0.08%
RVMD - XENE
48%
Loosely correlated
+2.21%
More